1-3 of 3
Mark Coyne
Close
Sort by
Journal Articles

Predictors of Healthcare Utilization in Newly Diagnosed Myeloma

Shane Toolan, MRCP, Mark Griffin, MB BCh BAO, Mark Coyne, Kate O'Mahony, BSc Pharm, Joy Lewis, Chandan D'Souza, Daniel G Connaghan, MD, Karen Murphy, MD, Kamal Fadalla, FRCPath, Joan Marie Fitzgerald, BSc, FRCPath, MBBChir, Conor Collins, Niall Swan, MRCP, MB, Crotty Tom, Gibbons David, Liam Smyth, MDFRCPath
Journal: Blood
Blood (2020) 136 (Supplement 1): 37–38.
https://doi.org/10.1182/blood-2020-138857
Published: 2020
Journal Articles

A Phase II Multi-Center Study of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone (RsqVD) in Newly Diagnosed Multiple Myeloma - Ctrial-IE (ICORG) 13-17 Study

Peter O'Gorman, MD PhD, Michael E O'Dwyer, MD, Oonagh Gilligan, MD, John Quinn, MD PhD, Mark Coyne, MD, Janusz Krawczyk, MD, Philip T Murphy, MD, Lourdes del Rosario McAlester, Orna Harraghy, Orlaith Cormican, Elizabeth Lenihan, Keith Egan, Meegahage Ratnakanthi Perera, MD, Gerard Crotty, Patrick J Hayden, MD, Brian Hennessy, MD MRCPI, FRCPath, Hilary M O'Leary, FRCPath, Kathleen Scott, PhD, Imelda Parker, PhD, Michele Cunnane, Jacinta Marron, Aoife Connell, Elizabeth Coghlan, Jacob P. Laubach, MD, Paul G. Richardson, MD
Journal: Blood
Blood (2016) 128 (22): 2117.
https://doi.org/10.1182/blood.V128.22.2117.2117
Published: 2016
Journal Articles

Is Treatment with Bortezomib for Multiple Myeloma or Amyloidosis Associated with Cytomegalovirus Reactivation?

Isobel Ramsay, Dunnya De-silva, Sarah Worthington, Mark Coyne, Ashutosh Wechalekar, Paul D Griffiths
Journal: Blood
Blood (2015) 126 (23): 4259.
https://doi.org/10.1182/blood.V126.23.4259.4259
Published: 2015